Guardant Health, Inc. (GH) – What Are Researchers Thinking About This Stock?

Guardant Health, Inc. (NASDAQ:GH) has received a consensus rating of “Moderate Buy” from the twenty-six ratings firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, twenty-four have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $191.00.

A number of equities research analysts have recently issued reports on the company. Evercore restated an “outperform” rating and issued a $200.00 price target on shares of Guardant Health in a research report on Monday, July 6th. Guggenheim upped their target price on Guardant Health from $190.00 to $200.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Stephens raised their target price on Guardant Health from $170.00 to $195.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. Citigroup lifted their price target on Guardant Health from $150.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Finally, Stifel Nicolaus upped their price objective on shares of Guardant Health from $130.00 to $180.00 and gave the company a “buy” rating in a report on Friday, July 31st.

Guardant Health Trading Up 2.5%

Shares of NASDAQ GH opened at $182.59 on Thursday. Guardant Health has a 12-month low of $68.02 and a 12-month high of $191.05. The stock has a market cap of $24.50 billion, a PE ratio of -52.32 and a beta of 1.58. The company has a 50-day moving average of $169.05 and a 200 day moving average of $129.95.

Guardant Health (NASDAQ:GH) last released its earnings results on Thursday, July 30th. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.34. The business had revenue of $334.98 million during the quarter, compared to analysts’ expectations of $314.23 million. The company’s revenue for the quarter was up 44.3% compared to the same quarter last year. During the same period last year, the business earned ($0.44) earnings per share. On average, sell-side analysts forecast that Guardant Health will post -3.08 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CTO Darya Chudova sold 7,738 shares of the stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $178.00, for a total value of $1,377,364.00. Following the completion of the transaction, the chief technology officer directly owned 70,635 shares in the company, valued at approximately $12,573,030. This represents a 9.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Amirali Talasaz sold 37,500 shares of the firm’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $169.16, for a total value of $6,343,500.00. Following the sale, the chief executive officer directly owned 37,500 shares of the company’s stock, valued at approximately $6,343,500. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 178,940 shares of company stock worth $30,070,911. 5.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Guardant Health

Large investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company acquired a new stake in Guardant Health during the 2nd quarter worth $208,592,000. William Blair Investment Management LLC purchased a new position in shares of Guardant Health during the second quarter worth about $196,737,000. Orbimed Advisors LLC acquired a new position in shares of Guardant Health in the first quarter valued at approximately $40,199,000. Eagle Health Investments LP acquired a new position in Guardant Health in the 2nd quarter valued at $45,112,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Guardant Health during the second quarter worth about $32,316,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company’s products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient’s response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.